Comparing Two Ways of Explaining Ketamine Treatment for Hard-to-Treat Depression
Compares two ways of explaining ketamine to adults with treatment-resistant depression.
Plain-language title generated from the registry record
Registry title: Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing
Key facts
- Where
- Skövde, SwedenSee the site
Where in Sweden
- Brain Stimulation Clinic, Skaraborg's HospitalSkövde, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Valdemar Landgren
- Trial code
- NCT07824973
- Record updated
- 17 September 2026
- Original description
Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing. The study will examine whether the framing affects depressive symptoms, treatment experience, tolerability, and longer-term outcomes.Read full original descriptionShow less
A Single-center Open-label Randomized Parallel-group Superiority Trial to Compare the Efficacy of Psychedelic and Biomedical Framing of Intravenous Ketamine for Treatment-resistant Depression - the KetSet Trial
Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing. The study will examine whether the framing affects depressive symptoms, treatment experience, tolerability, and longer-term outcomes.
Inclusion: Prescribed ketamine treatment for depression; Able to understand study information and provide informed consent.
Exclusion: Patients who do not meet the inclusion criteria.